Enhanced antibody half-life improves in vivo activity

Improved affinity for the neonatal Fc receptor (FcRn) is known to extend antibody half-life in vivo. However, this has never been linked with enhanced therapeutic efficacy. We tested whether antibodies with half-lives extended up to fivefold in human (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing intervals. We observed that prolonged exposure due to FcRn-mediated enhancement of half-life improved antitumor activity of Fc-engineered antibodies in an hFcRn/Rag1−/− mouse model. This bridges the demand for dosing convenience with the clinical necessity of maintaining efficacy.

[1]  N. Tsurushita,et al.  An Engineered Human IgG1 Antibody with Longer Serum Half-Life , 2006, The Journal of Immunology.

[2]  J. Mendelsohn,et al.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma , 1993, Cancer Immunology, Immunotherapy.

[3]  Y G Meng,et al.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.

[4]  S. Morrison,et al.  Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. , 2006, Molecular immunology.

[5]  J. Marvin,et al.  Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.

[6]  Ying Tang,et al.  Monoclonal Antibody Clearance , 2007, Journal of Biological Chemistry.

[7]  Herren Wu,et al.  Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)* , 2006, Journal of Biological Chemistry.

[8]  J. Mendelsohn,et al.  Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. , 1994, The Journal of biological chemistry.

[9]  J. Tso,et al.  Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates* , 2004, Journal of Biological Chemistry.

[10]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[11]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[12]  P. Parren,et al.  Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. , 2006, Cancer research.

[13]  Leonard G Presta,et al.  Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. , 2006, International immunology.

[14]  Leonard G Presta,et al.  Molecular engineering and design of therapeutic antibodies. , 2008, Current opinion in immunology.